Products ({{ products.totalElements }})
News & articles ({{ wpNewsAndArticles.total_posts }})
Blog entries ({{ wpBlogEntries.total_posts }})

{{ String(product.attributes.name) }} {{ String(product.attributes.productType) }} - NEW	{{ String(product.attributes.artNo) }}	{{ (String(product.attributes.sizeStr) != 'undefined') ? String(product.attributes.sizeStr) : '–' }}	Not available On Request {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} Login for price

Full search results →

No products found

News {{ news.date \| formatDate }} #{{tag.name}}

No news & articles found

Full search results →

blog entry {{ blogEntry.date \| formatDate }}

No blog entries found

Full search results →

Concanamycin A (high purity)

Chemicals & Biochemicals

Make a customized order

Article No

BVT-0237-C025

Size

25 ug

Shipping Information

Article No

BVT-0237-C025

Size

25 ug

Specifications

CAS No	80890-47-7
MW	866.1
Article No	BVT-0237-C025
Country Availability	SE, FI, DK, NO, IS, EE, LV, LT
Description	Concanamycin A (high purity)
Supplier	Adipogen Life Sciences
Format	Powder
Notes	Antibiotic. More potent and specific H+-ATPase inhibitor than bafilomycin A1 (Prod. No. BVT-0252). Inhibits acidification of organelles such as lysosomes and the Golgi apparatus. Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases. Blocks cell surface expression of viral glycoproteins without affecting their synthesis. Cytotoxic in a number of cell lines in a cell viability assay. Induces nitric oxide (NO) production. Concanamycin A enables the immune system to kill HIV-infected cells. Nef is an HIV-encoded accessory protein that enhances pathogenicity by down-regulating major histocompatibility class I (MHC-I) expression to evade killing by cytotoxic T lymphocytes (CTLs). Concanamycin A has been identified as potent inhibitor of Nef that restores MHC-I and enhances the clearance of HIV-infected primary cells by cytotoxic T lymphocytes. Concanamycin A counteracts Nef from diverse clades of HIV targeting multiple allotypes of MHC-I, indicating the potential for broad therapeutic utility.\|Chemical. CAS: 80890-47-7. Formula: C46H75NO14. MW: 866.1. Isolated from Streptomyces sp. Antibiotic. More potent and specific H+-ATPase inhibitor than bafilomycin A1 (Prod. No. BVT-0252). Inhibits acidification of organelles such as lysosomes and the Golgi apparatus. Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases. Blocks cell surface expression of viral glycoproteins without affecting their synthesis. Cytotoxic in a number of cell lines in a cell viability assay. Induces nitric oxide (NO) production.
Molecular Formula	C46H75NO14
Alias Names	Folimycin; Antibiotic TAN 1323B; Antibiotic X4357B
Product Type	Chemicals & Biochemicals
Purity	>98%
Research area	Cell Death
Shipping Information	RT
Size	25 ug
Solubility	Soluble in methanol, DMSO or acetonitrile; insoluble in water.
Stability	Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C.
Storage	-20°C, 4°C
Technical Specifications	Chemical. CAS: 80890-47-7. Formula: C46H75NO14. MW: 866.1. Isolated from Streptomyces sp. Antibiotic. More potent and specific H+-ATPase inhibitor than bafilomycin A1 (Prod. No. BVT-0252). Inhibits acidification of organelles such as lysosomes and the Golgi apparatus. Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases. Blocks cell surface expression of viral glycoproteins without affecting their synthesis. Cytotoxic in a number of cell lines in a cell viability assay. Induces nitric oxide (NO) production.
Product Page Updated	2024-02-01T08:25:01.492Z

Documentation

Datasheet

MSDS

References

Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. 37, 1333 (1984) | Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus: M. Muroi, et al.; Cell Struct. Funct. 18, 139 (1993) | Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins: M. Muroi, et al.; BBRC 193, 999 (1993) | Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases: S. Drose, et al.; Biochemistry 32, 3902 (1993) | Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268, 19092 (1993) | Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2), 381 (1995) | Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death: T. Nishihara, et al.; BBRC 212, 255 (1995) | Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c: M. Huss, et al.; J. Biol. Chem. 277, 40544 (2002) | Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells: J. Hong, et al.; J. Pharmacol. Exp. Ther. 319, 672 (2006) | Degradation of oxidized proteins by autophagy during oxidative stress in Arabidopsis: Y. Xiong, et al.; Plant Physiol. 143, 291 (2007) | Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins: J.A. Sobota, et al.; J. Cell Sci. 122, 3542 (2009) | Inhibitors of V-ATPase: old and new players: M. Huss, et al.; J. Exp. Biol. 212, 341 (2009) | Increased production of reactive oxygen species by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells: A. Yokomakura, et al.; J. Toxicol. Sci. 37, 1045 (2012) | Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes: V. Horova, et al.; FEBS J. 280, 3436 (2013) | Estimating the rotation rate in the vacuolar proton-ATPase in native yeast vacuolar membranes: Z. Ferencz, et al.; Eur. Biophys. J. 42, 147 (2013) | Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion: V. Michel, et al.; Int. J. Cancer 132, E1 (2013) | Loss of vacuolar H+-ATPase activity in organelles signals ubiquitination and endocytosis of the yeast plasma membrane proton pump Pma1p: A. M. Smardon & P. M. Kane; J. Biol. Chem. 289, 32316 (2014) | Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells: H. Jin, et al.; Toxicol. Appl. Pharm. 278, 17 (2015)

Shipping info

The delivery time for this item is approximately 5-8 business days. Read more